Oncogenic signatures mapped in TCGA aid in development of personalized therapy

Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper published in Nature Genetics supports a new approach: one based on the genomic signature of a tumor rather than the tissue of origin in the body.